Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices

Splenectomy for immune thrombocytopenia: down but not out

(2018) Shruti Chaturvedi et al.   BLOOD

Eltrombopag in Combination with Azacitidine for First-Line Treatment of MDS Patients with Thrombocytopenia: The Randomized, Placebo-controlled, Phase III, Support Study

(2017) M. Dickinson et al.   LEUKEMIA RESEARCH

A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia

(2016) Russell K. Brynes et al.   ACTA HAEMATOLOGICA

Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia

(2016) John Chapin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years

(2016) Francesca Palandri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia

(2016) M. Mahevas et al.   BLOOD

How I treat refractory immune thrombocytopenia

(2016) A. Cuker et al.   BLOOD

Eltrombopag, a potent stimulator of megakaryopoiesis

(2016) H. Raslova et al.   HAEMATOLOGICA

Eltrombopag, a potent stimulator of megakaryopoiesis

(2016) H. Raslova et al.   HAEMATOLOGICA

The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)

(2015) Patrizio Mazza et al.   ANNALS OF HEMATOLOGY

A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP

(2015) H. Zhou et al.   BLOOD

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study

(2015) Adrian Newland et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults

(2015) Libor Červinek et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim

(2015) David J. Kuter et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Waleed Ghanima et al.   LANCET

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

(2015) Emma Harris et al.   Current Rheumatology Reports

Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis

(2015) Shaan Chugh et al.   Lancet Haematology

Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.

(2014) Romain Levy et al.   AUTOIMMUNITY REVIEWS

A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)

(2014) Huyen Tran et al.   BRITISH JOURNAL OF HAEMATOLOGY

Use of eltrombopag after romiplostim in primary immune thrombocytopenia

(2014) José Ramón González-Porras et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

(2014) J. B. Bussel et al.   HAEMATOLOGICA

Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

(2014) Tomás José González-López et al.   PLATELETS

Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia

(2013) S. Boyle et al.   BLOOD

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

(2013) David J. Kuter et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

(2013) Francesco Rodeghiero et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

(2013) S. Y. Kristinsson et al.   HAEMATOLOGICA

The biology of thrombopoietin and thrombopoietin receptor agonists

(2013) David J. Kuter   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

(2013) Bahareh Ghadaki et al.   TRANSFUSION

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment

(2012) W. Ghanima et al.   BLOOD

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

(2012) James B. Bussel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

(2012) Carla Casulo et al.   Clinical Lymphoma Myeloma & Leukemia

Positioning new treatments in the management of immune thrombocytopenia

(2012) Donald M. Arnold   PEDIATRIC BLOOD & CANCER

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Low-dose rituximab in adult patients with primary immune thrombocytopenia

(2010) Francesco Zaja et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

(2009) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

(2008) B. Godeau et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials

(2008) James N. George et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET

Is splenectomy still the gold standard for the treatment of chronic ITP?

(2007) Francesco Rodeghiero et al.   AMERICAN JOURNAL OF HEMATOLOGY

Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura

(2007) Robert McMillan et al.   AMERICAN JOURNAL OF HEMATOLOGY